Lilly Suzhou Pharmaceutical Expands Insulin Plant
This article was originally published in PharmAsia News
Executive Summary
Lilly Suzhou Pharmaceutical recently held a ground-breaking ceremony for its Suzhou plant expansion project. With an investment of more than $40 million, the plant will cover an area of 50,000 square meters, 60 percent bigger than the current factory, and will be used mainly for packaging and storing insulin products. After completion of the project, both the existing and new plants will produce insulin products. The new plant will help Lilly increase its insulin production capacity to meet China's growing pharmaceutical market needs. (Click here for more - Chinese Language)
You may also be interested in...
Display Of IP Strength In China: Lilly Wins Patent Dispute For Cialis Against Domestic Chinese Company
SHANGHAI - Eli Lilly's win of the patent infringement suit in China against Jiangyin Dongfang Pharmaceutical for manufacturing tadalafil, the active ingredient in Lilly's male erectile dysfunction drug Cialis, is good news for multinational companies operating in China
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.